A new in vitro uranium sequestration assay to analyze the effectiveness of 3,4,3-LI(1,2-HOPO) in reducing the harmful effects of this actinide on bone cells.
Environ Toxicol Pharmacol
; 110: 104518, 2024 Sep.
Article
de En
| MEDLINE
| ID: mdl-39067717
ABSTRACT
Environmental or occupational exposure to natural uranium can have adverse health effects, with its chemical toxicity being mainly directed towards the kidneys and skeleton. This has led to the development of chelating agents to remove uranium from the human body, including the ligand 3,4,3-LI(1,2-HOPO). We have developed a new in vitro assay to assess the efficacy of 3,4,3-LI(1,2-HOPO) in attenuating uranium-induced bone cell damage. This approach uses osteoclasts whose formation and function are altered by exposure to uranium. This assay is an interesting and effective alternative to animal methods for assessing the efficacy and safety of new uranium decorporants.
Mots clés
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Ostéoclastes
/
Uranium
Limites:
Animals
/
Humans
Langue:
En
Journal:
Environ Toxicol Pharmacol
/
Environ. toxicol. pharmacol
/
Environmental toxicology and pharmacology
Année:
2024
Type de document:
Article
Pays de publication:
Pays-Bas